JP5619352B2 - 細菌を処置するための組成物および方法 - Google Patents

細菌を処置するための組成物および方法 Download PDF

Info

Publication number
JP5619352B2
JP5619352B2 JP2008524245A JP2008524245A JP5619352B2 JP 5619352 B2 JP5619352 B2 JP 5619352B2 JP 2008524245 A JP2008524245 A JP 2008524245A JP 2008524245 A JP2008524245 A JP 2008524245A JP 5619352 B2 JP5619352 B2 JP 5619352B2
Authority
JP
Japan
Prior art keywords
nisin
mupirocin
bacteria
treatment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008524245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502965A5 (https=
JP2009502965A (ja
Inventor
スコット マイケル ウォルシュ
スコット マイケル ウォルシュ
キャサリン ピッタウェイメアリー
メアリー キャサリン ピッタウェイ
ジェイムズ ジェイ． モンド
ジェイムズ ジェイ． モンド
Original Assignee
バイオシネクサス インコーポレーティッド
バイオシネクサス インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオシネクサス インコーポレーティッド, バイオシネクサス インコーポレーティッド filed Critical バイオシネクサス インコーポレーティッド
Publication of JP2009502965A publication Critical patent/JP2009502965A/ja
Publication of JP2009502965A5 publication Critical patent/JP2009502965A5/ja
Application granted granted Critical
Publication of JP5619352B2 publication Critical patent/JP5619352B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2008524245A 2005-07-28 2006-07-28 細菌を処置するための組成物および方法 Expired - Fee Related JP5619352B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70301005P 2005-07-28 2005-07-28
US60/703,010 2005-07-28
US72519305P 2005-10-11 2005-10-11
US60/725,193 2005-10-11
US77903406P 2006-03-03 2006-03-03
US60/779,034 2006-03-03
PCT/US2006/029672 WO2007014372A2 (en) 2005-07-28 2006-07-28 Compositions and methods for treating bacteria

Publications (3)

Publication Number Publication Date
JP2009502965A JP2009502965A (ja) 2009-01-29
JP2009502965A5 JP2009502965A5 (https=) 2012-07-26
JP5619352B2 true JP5619352B2 (ja) 2014-11-05

Family

ID=37684026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008524245A Expired - Fee Related JP5619352B2 (ja) 2005-07-28 2006-07-28 細菌を処置するための組成物および方法

Country Status (6)

Country Link
US (2) US7517852B2 (https=)
EP (1) EP1940437B1 (https=)
JP (1) JP5619352B2 (https=)
CA (1) CA2617133C (https=)
ES (1) ES2436614T3 (https=)
WO (1) WO2007014372A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517852B2 (en) * 2005-07-28 2009-04-14 Biosynexus Incorporated Compositions and methods for treating bacteria
WO2007044745A1 (en) * 2005-10-11 2007-04-19 Biosynexus Incorporated Lantibiotic and mupirocin compositions for treating bacterial infections
US9115358B2 (en) 2006-08-11 2015-08-25 President And Fellows Of Harvard College Moenomycin biosynthesis-related compositions and methods of use thereof
US9427468B2 (en) * 2007-08-22 2016-08-30 Trustees Of Dartmouth College Compositions and methods for diagnosing and treating community-acquired methicillin-resistant Staphylococcus aureus
EP2205074A4 (en) * 2007-10-04 2013-07-31 Harvard College MOENOMYCIN ANALOGUE, SYNTHESIS PROCESS AND USE
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
JP5374260B2 (ja) * 2009-07-10 2013-12-25 静岡商工会議所 農業用資材
WO2012033634A2 (en) * 2010-09-09 2012-03-15 Mary Kay Inc. Topical skin care formulations comprising plant extracts
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
WO2012125941A1 (en) * 2011-03-17 2012-09-20 Follica, Inc. Lithium treatment for microbial infections
US9918479B2 (en) 2012-02-28 2018-03-20 Marrone Bio Innovations, Inc. Control of phytopathogenic microorganisms with Pseudomonas sp. and substances and compositions derived therefrom
WO2013152277A2 (en) 2012-04-06 2013-10-10 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
EP2850090B1 (en) 2012-04-06 2018-10-03 President and Fellows of Harvard College Chemoenzymatic methods for synthesizing moenomycin analogs
EP2850091A1 (en) 2012-04-06 2015-03-25 President and Fellows of Harvard College Methods and compounds for identifying glycosyltransferase inhibitors
EP3194609B1 (en) 2014-09-16 2019-08-28 President and Fellows of Harvard College Engineered water nanostructures (ewns) and uses thereof
US10617703B2 (en) * 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US12502370B2 (en) * 2019-04-11 2025-12-23 Cmpd Licensing, Llc Wound treatments and compositions
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
EP3331496B1 (en) * 2015-08-05 2021-01-27 The University of Rochester Antimicrobial compositions comprising mupirocin and neomycin
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
AU2017240069B2 (en) 2016-03-31 2024-03-07 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2017173240A1 (en) 2016-03-31 2017-10-05 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
EP3435765A1 (en) 2016-03-31 2019-02-06 Gojo Industries, Inc. Antimicrobial peptide stimulating sanitizing composition
EP3544575A1 (en) 2016-11-23 2019-10-02 GOJO Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
EP3701367B1 (en) 2017-10-27 2022-06-01 Canon Production Printing Holding B.V. Controller for a multi-roll printer, printing system and method for controlling a multi-roll printer
WO2020185562A1 (en) * 2019-03-08 2020-09-17 Fraunhofer Usa, Inc. Novel antimicrobial lantibiotic peptide and uses thereof
US12156875B2 (en) 2019-04-11 2024-12-03 Cmpd Licensing, Llc Wound treatments and compositions
US12433853B2 (en) 2019-08-26 2025-10-07 Kent State University Rationally designed lawsone derivatives as antimicrobials against multidrug-resistant Staphylococcus aureus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135910A (en) * 1988-06-22 1992-08-04 The Public Health Research Institute Of The City Of New York Nisin compositions for use as enhanced, broad range bactericides
US5260271A (en) 1988-06-22 1993-11-09 Applied Microbiology, Inc. Nisin compositions for use as enhanced broad range bactericides
DK0579730T3 (da) * 1991-04-11 2003-03-31 Stichting Nl I Voor Zuivelonde Nisin A-lignende lantibiotika, mælkesyrebakterie der producerer sådanne lantibiotika, fremgangsmåde til konstruktion af sådanne mælkesyrebakterier og fremgangsmåde til konservering . . .
ES2157985T3 (es) 1993-08-20 2001-09-01 Novartis Ag Metodo para la prevencion y el tratamiento de la mastitis bovina.
GB9423404D0 (en) * 1994-11-19 1995-01-11 Biotech & Biolog Scien Res Production of nisin
CN1138560C (zh) * 1995-06-23 2004-02-18 Ambi股份有限公司 控制对抗生素耐药的革兰氏阳性细菌的方法和治疗感染的方法
US5928146A (en) * 1996-03-15 1999-07-27 Hitachi Medical Corporation Inspection apparatus using nuclear magnetic resonance
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
CO4910145A1 (es) * 1996-10-01 2000-04-24 Smithkline Beecham Corp Uso
IL123143A (en) * 1998-02-02 2001-08-26 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
IL137363A (en) * 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
ES2532906T5 (es) * 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
AU2003296937A1 (en) * 2002-12-10 2004-06-30 Biosynexus Incorporated Topical anti-infective formulations
US7517852B2 (en) * 2005-07-28 2009-04-14 Biosynexus Incorporated Compositions and methods for treating bacteria
WO2007044745A1 (en) * 2005-10-11 2007-04-19 Biosynexus Incorporated Lantibiotic and mupirocin compositions for treating bacterial infections

Also Published As

Publication number Publication date
US8697639B2 (en) 2014-04-15
US20090196945A1 (en) 2009-08-06
WO2007014372A3 (en) 2007-07-26
WO2007014372A2 (en) 2007-02-01
US7517852B2 (en) 2009-04-14
US20070060506A1 (en) 2007-03-15
EP1940437A2 (en) 2008-07-09
JP2009502965A (ja) 2009-01-29
EP1940437B1 (en) 2013-09-04
EP1940437A4 (en) 2009-08-19
ES2436614T3 (es) 2014-01-03
CA2617133A1 (en) 2007-02-01
CA2617133C (en) 2014-09-30

Similar Documents

Publication Publication Date Title
JP5619352B2 (ja) 細菌を処置するための組成物および方法
US20090304783A1 (en) Compositions and methods for treating bacteria
RU2607660C2 (ru) Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент
Hidalgo et al. Infections in critically ill burn patients
JP7118022B2 (ja) 細菌性バイオフィルムを除去するためのセアプローゼの使用
US9173972B2 (en) Methods and compositions for promoting wound healing
Weber et al. Antibiotic prophylaxis in clean-contaminated head and neck oncologic surgery
CN105492005A (zh) 治疗包括乳房炎的微生物感染的方法
O'Reilly et al. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin
US20210260101A1 (en) Potentiated antibiotic compositions and methods of use for treating bacterial infections and biofilms
EP1200463B1 (en) Antimicrobial histone h1 compositions and methods of use thereof
Pawar et al. Comparison of in vitro antibacterial activity of streptomycin-diclofenac loaded composite biomaterial dressings with commercial silver based antimicrobial wound dressings
Pachón-Ibáñez et al. Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin
MX2012010013A (es) Composiciones para administracion topica.
US20070238652A1 (en) Neutralization of bacterial spores
Nakhla et al. Microbiological aspects of burns at Mount Vernon Hospital, UK
Yasim et al. Efficacy of vancomycin, teicoplanin and fusidic acid as prophylactic agents in prevention of vascular graft infection: an experimental study in rat
CN118251216A (zh) 用于生物膜破坏的方法
WO2017019943A1 (en) Antimicrobial formulations and applications thereof
Gardam et al. Disinfectants and Antiseptics
Shankar et al. Newer antibiotics
van Saene et al. A Possible Explanation for the Success of SDD
Bébéar Pre-clinical Microbiology—Atypical Organisms
NZ523982A (en) Combinations of dalfopristine / quinupristine with cefpirome useful in bactericidal or bacteriostatic treatment
WO2002000247A1 (en) Reversal of antibiotic resistance with lysozyme dimer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120607

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140917

R150 Certificate of patent or registration of utility model

Ref document number: 5619352

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees